bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract 4507: Deletion of 9p21.3/p16/CDKN2A is associated with poorer survival in primary central nervous system (PCNSL) lymphoma independent of 6q22 effect. A study facilitated by the Surveillance, Epidemiology and End Results Tissue Repository Program (SEER TRP)
Authors: O'neill Brian Patrick , Decker Paul A. , Macon William R. , McPhail Ellen D. , Law Mark , Cerhan James R. 
Published: August 2012

Abstract
Objective. Molecularly distinct PCNSL signatures with divergent clinical behavior are now recognized. Implied within this heterogeneity are mechanisms for treatment response and pattern of failure. Recent cytogenetic and genomic studies demonstrated influences of select chromosomal regions on outcome to treatment and survival. These included genetic and epigenetic alterations affecting CDKN2A (9p21.3) that distinguished PCNSL from its systemic counterpart. We now report that deletion of 9p21.3/p16 is associated with a negative effect on survival. Methods and Patients. Well-annotated and population-based formalin fixed paraffin embedded (FFPE) patient samples were sourced from the SEER TRP. Specimens were retrieved from the Hawaii, Iowa and Los Angeles County (LA Co) tissue repositories. “Home Brew” fluorescent in situ hybridization (FISH) probes for BCL6, and ptpr-α were prepared according to a standard protocol (Cady et al. J Clin Oncol 2008;26:4814-9). FISH probes for 9p.21 were prepared similarly and then compared to a commercially available probe. Survival was based on the SEER TRP clinical annotations. Results. Thirty five patients were sourced - twelve from Iowa, 13 from Hawaii, and 10 from LA County. The test cohort was 23 from Iowa and Hawaii; the FISH probe failed in 9 and three had insufficient remaining tumor for analysis. For the Iowa and Hawaii registries and for the registries combined the lack of FISH probe detection of 9p.21/p16 correlated with survival (p=0.0159) and was independent of BCL6 (p=0.8788) and ptpr-α (p=0.3724). Conclusion. Deletion of p16 confers a negative effect on survival of PCNSL patients and appears to be independent of treatment, age, BCL6 and ptpr-α status. These results need to be confirmed in a larger sample size. 9p21.3 detection by FISH in feasible in surgical specimens and may aid in the stratification of such patients into different and/or more intensive treatment regimens.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4507. doi:1538-7445.AM2012-4507
Abstract 4508: Oxidative protein modifications in serous epithelia ovarian cancer tissues
Authors: Mehrabi Sharifeh , Vatcharapirjon Yupha , Mehreteab Tesfamariam , Adams Gregory , Aikhionbare Felix O. 
Published: August 2012

Abstract
Despite advances in the surgical and chemotherapeutic management of ovarian cancer over the last decade, survival rates remain low, largely due to late diagnosis. Up to now very few candidate biomarkers have been investigated for early detection of ovarian cancer. The implication of ROS in female reproductive system and ovarian cancer are evidenced. Enzymatic antioxidants neutralize excessive ROS in cells. Under special condition, the cellular antioxidants are depleted. The ultimate aim of this study is to identify a biomarker for early detection of ovarian cancer. In this study 155 snap-freeze primary serous epithelial ovarian tissues including, normal, normal surrounding, cystadenoma, borderline and carcinoma with age range of 65±12,(55% Caucasian 45% Africa American), were analyzed. The objectives are: (a) to evaluate the protein expression profiles using two dimension gel electrophoresis (2-D SDS-PAGE) and LC/MS technology, (b) to identify and evaluate the level of oxidative modified protein, using derivatisation of protein carbonyl group with 2,4-dinitrophenylhyrdozine(DNPH) assay and western blot technique. Our results showed that the index of carbonyl protein /total protein increased by onset and progression of the serous ovarian malignancy. The elevation of oxidized protein among African American was 40 % higher than Caucasian in advanced stages of diseases. SDS-PAGE profiles showed a distinct protein pattern among cancerous and non-cancerous tissues. LC/MS analysis for elucidation of molecular changes of selected proteins bands is in progress.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4508. doi:1538-7445.AM2012-4508
Abstract 4512: AT rich interactive domain 3A (ARID3A) overexpression correlates with good prognosis in colorectal cancer
Authors: Song Meiying , Shin Chang Hoon , Park Misun , Kim Hoguen , Kim Hyunki 
Published: August 2012

Abstract
AT Rich Interactive Domain 3A (ARID3A) is a member of the ARID family of DNA-binding proteins. Previous studies have shown that ARID3A controls the cell growth through p53-dependent manner, whereas its significance in the prognosis of colorectal cancer (CRC) is not yet fully understood. In this study, formalin-fixed, paraffin-embedded tumors and matched normal mucosae from 690 patients who underwent surgery for CRC were constructed into tissue microarrays. The expression of ARID3A was investigated by immunohistochemistry. We detected a nuclear positive expression of ARID3A in a subset of colorectal cancers, whereas ARID3A was completely negative in all normal mucosae. Of the 690 cases, 195 tumors (28.3%) were strong positive for ARID3A, 187 tumors (27.1%) were weak positive and 308 tumors (44.6%) were negative. We examined p53 expression status by immunohistochemistry simultaneously. Among the 690 tumors, 358 tumors (51.9%) were positive for p53 expression and 332 tumors (48.1%) were negative for p53 expression. Kaplan-Meier method and Cox proportional hazards modeling were used to analyze the overall survival between ARID3A negative or weak expression group and ARID3A strong expression group. The ARID3A expression in CRCs was significantly correlated with age (P=0.003), degree of differentiation (P&lt;0.001), depth of invasion (P=0.001), lymph node metastasis (P=0.008), distant metastasis (P=0.007), TNM stage (P&lt;0.001), status of microsatellite instability (P&lt;0.001), and CEA levels (P=0.003). Moreover, the strong expression of ARID3A and the negativity of p53 were statistically correlated (P=0.045). The survival of CRC patients with ARID3A strong expression was significantly longer than that of patients with ARID3A negative or weak expression (P=0.002), however the effect of ARID3A on the survival rate of CRCs might differ by p53 status. Combined analysis of ARID3A and p53 expression indicated that CRC group with ARID3A-strong positive and p53-negative showed better prognosis compared with the remaining groups (P=0.003). On multivariate analysis, ARID3A overexpression was proven to be an independent predictor for better prognosis in CRC (95% CI: 0.44-0.96; P=0.031). In conclusion, this study strongly suggests the usefulness of ARID3A as a biomarker to predict the prognosis of colorectal cancer.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4512. doi:1538-7445.AM2012-4512
Abstract 4515: Low serum levels of a novel anti-inflammatory fatty acid as a new risk factor for colorectal cancer
Authors: Ritchie Shawn A. , Tonita Jon , Alvi Riaz , Lehotay Denis , Elshoni Hoda , McHattie James , Goodenowe Dayan 
Published: August 2012

Abstract
Low serum levels of novel, long-chain, hydroxylated and polyunsaturated fatty acids (GTAs) in colorectal cancer (CRC) patients has been previously reported. This study prospectively investigated the relationship between serum GTA levels and CRC incidence among subjects undergoing colonoscopy. Serum samples and pathology data were collected from 4923 representative subjects undergoing colonoscopy in a typical, non-screening, colonoscopy population and from 964 representative age and geographically-matched subjects from the general population. Serum GTA-446 levels were determined on all subjects using a sensitive tandem mass spectrometric method. A low serum GTA-446 level was defined as a GTA-446 concentration below the tenth percentile of 40-49 year-olds in the general population sampling. Eighty-six percent of newly diagnosed CRC subjects (87% for stage 0-II and 85% for stage III-IV) were observed to have low serum GTA-446 levels, with a PPV of 15% and NPV of 99.7%. CRC incidence was observed to increase significantly with age in all subjects (p&lt;0.05) and in low GTA-446 subjects (p&lt;0.05), but not in subjects with normal serum GTA-446 levels (p=0.86). The CRC incidence rate in subjects with low GTA-446 levels (3.1%) was over six times higher than for subjects with normal GTA-446 levels (0.5%) and approximately twice that of subjects with GI symptoms (2.0%). The results indicate that a low serum GTA-446 level is a significant risk factor for CRC and a sensitive predictor of early-stage disease, and that low-GTA levels could be responsible for the age-associated increase in CRC incidence. Implications for population-wide screening are discussed.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4515. doi:1538-7445.AM2012-4515
Abstract 4516: Gene expression analysis as a biomarker study for ACTS-CC trial (TRICC0706), a phase III trial for adjuvant chemotherapy of S-1 and UFT/LV against stage III colon cancer in Japan
Authors: Uetake Hiroyuki , Ishikawa Toshiaki , Matsui Shigeyuki , Sugihara Kenichi 
Published: August 2012

Abstract
Background: The ACTS-CC trial is a phase III trial designed to validate non-inferiority of S-1 to UFT/ LV, a standard treatment in Japan as adjuvant chemotherapy for stage III colon cancer and the initial safety report of the trial was reported in ASCO 2011. In biomarker study of ACTS-CC trial, gene expression levels were studied using formalin fixed and paraffin embedded (FFPE) specimens. Methods: Blocks from resected colorectal cancer specimens were obtained under informed consent for this biomarker study from 892 patients enrolled between Apr.2009 and Jan.2010. Gene expression levels of 11 enzymes (TS, DPD, TP, OPRT, FPGS, GGH, DHFR, MTHFR, MTHFD, FOLRA, GART), that correlate to 5-FU and folic acid metabolism, are studied according to Danenberg Tumor ProfileTM method (Shirota, Y. JCO 2001). Correlation coefficients between gene expressions of the 11 enzymes were computed using Spearman rank correlation test (Rs). Results: Gene expression levels were successfully estimated in 521-808 samples (84.0-90.0%, 89.4% in median). Highest Rs was observed between DPD and TP (0.68. 95% confidence interval; 0.64-0.71). Classifying Rs value into 3 groups (positive (0.5&lt;), week (0.31-0.50) and negative (0.3 or less)), TS and OPRT had positive or week correlation with 4 of 7 metabolic enzymes of folic acid (DHFR, MTHFR, MTHFD, and GART). Conclusions: This is the first and largest gene expression analysis for metabolic enzymes of 5-FU and folic acid. Positive correlation was observed between gene expression level of DPD and TP, which are DNA catabolic enzymes. Gene expression level of TS and OPRT, which are DNA synthetic enzymes, had correlation with metabolic enzymes of folic acid.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4516. doi:1538-7445.AM2012-4516
Abstract 4524: Characterization of 28 patient derived colorectal cancer xenografts and analysis for response markers to an antiangiogenic treatment
Authors: Rivera Maria , Becker Michael , Schlag Peter M. , Schwan Alexandra , Merk Johannes , Rosenthal Andre , Hinzmann Bernd , Hoffmann Jens , Fichtner Iduna 
Published: August 2012

Abstract
We have recently described an extended panel of new primary human CRC xenografts and their preclinical chemo-sensitivity to anti-cancer drugs (Poster 1584/3 AACR Annual Meeting 2010). These models consider more thoroughly the heterogeneity and genetic instability of tumors in a way ultimately enabling treatment decisions on an individualized basis. The approach is based on large scale screening for activity in new in vivo models combined with extensive characterization of these models (gene expression and mutations). Bioinformatic methods are used to further evaluate the mechanism of action of new drugs in colorectal cancer, to investigate possible resistance mechanisms and provide a rationale for combination therapies. Here we describe the evaluation of an antiangiogenic treatment in this panel of primary patient derived colorectal cancer models. Primary colon carcinoma tissue samples were collected using a standardized procedure. Tumor pieces were transplanted into immunodeficient mice immediately after surgery. A panel of 28 stably passagable colon cancer xenografts could be established as permanent tumor models. The results obtained so far, show that these patient-derived colon cancer models feature a high coincidence with the original tumor regarding histology and gene expression profiling. Response analysis in a subset of 19 xenografts evaluating the treated-to-control (T/C) ratios of tumor volumes revealed that the human specific VEGF antibody bevacizumab induces a meaningful biological effect (T/C below 50%) in 13 of 19 models. A first comparative genome-wide gene expression analyses of this subset revealed reasonable genes and pathways possibly involved in bevacizumab sensitivity. We will extend this investigation to all 28 tumor models in order to enhance the statistical robustness of the preliminary data. Our approach demonstrates that analysis of drug sensitivity together with bioinformatics correlations can provide candidate markers for further studies. An early implementation of such an approach in the drug development process could be helpful for the identification of predictive markers helping to select tumors likely to benefit from the drug as well as provide a rationale for combinations to be tested in clinical trials. These new strategies may help to better integrate research results in clinical development and may increase the success of new anti-cancer drugs in clinical studies.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4524. doi:1538-7445.AM2012-4524
Abstract 453: Prognostic value of 18F-FDG PET/CT in nasopharyngeal carcinoma
Authors: Huang Ying , Xiao WeiWei , Su ShengFa , Chen Yong , Han Fei , Teh Bin S. , Lu TaiXiang 
Published: August 2012

Abstract
Background: To investigate the prognostic value of pretreatment tumor maximal standardized uptake (SUVmax) values of 18F-FDG PET/CT in nasopharyngeal carcinoma (NPC) patients treated with intensity-modulated radiotherapy (IMRT). Methods: Consecutive biopsy-proven, non-metastatic NPC patients undergoing pretreatment 18F-FDG PET/CT and receiving IMRT from 2002 to 2005 were retrospectively reviewed. SUVmax of primary tumor (SUVmax-T) and regional lymph nodes (SUVmax-N) was measured. Survival was estimated using the Kaplan-Meier method. Prognostic significance was assessed using univariate and multivariate analyses. Results: One hundred sixty-nine eligible patients were enrolled, with 132 male and 37 female. Median age was 42 years. The distribution of stages was 14 for I, 39 for II, 61 for III and 55 for IV. Median SUVmax-T was 4.0 and median SUVmax-N was 3.5. Median follow-up was 71 months. Thirty five patients died and distant metastasis was the main reason of death (71.4%). Among 134 living patients, most patients are disease free (92.6%). In univariate analysis, older age, advanced T stage, advanced N stage, advanced clinical stage, higher SUVmax-T and higher SUVmax-N were all associated with lower OS, DFS and DMFS (Table 1). Remarkably, multivariate analysis found SUVmax-T and SUVmax-N were significant prognostic factors for OS, DFS and DMFS, independent of T and N stage (Table 1). Conclusion: SUVmax-T and SUVmax-N have prognostic value for survivals in IMRT-treated NPC patients. High FDG uptake in primary tumor and regional lymph nodes are useful for the identification of patients at higher risk. Abbreviations: OS, overall survival; DFS, disease-free survival; DMFS, distant metastasis-free survival; uni, univariate analysis; multi, multivariate analysis Table 1.

Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 453. doi:1538-7445.AM2012-453
Abstract 4531: Fucosylated haptoglobin is a novel type of cancer biomarker linked to the prognosis after an operation in colorectal cancer
Authors: Shinzaki Shinichiro , Takeda Yuri , Moriwaki Kenta , Murata Kohei , Miyoshi Eiji 
Published: August 2012

Abstract
Background: Fucosylation is a crucial oligosaccharide modification in cancer and inflammation. Total cellular proteins of cancer cells and the sera of patients with cancer both show increased fucosylation levels. Certain kinds of fucosylated proteins can be applied as novel cancer biomarkers in glyco-proteomic analyses. We previously identified fucosylated haptoglobin (Fuc-Hpt) as a serologic marker for pancreatic cancer, and recently developed a lectin-antibody enzyme-linked immunosorbent assay system for quantifying Fuc-Hpt. In the present study, we investigated the clinical outcome of Fuc-Hpt levels in patients with colorectal cancer (CRC), and examined the mechanisms underlying Fut-Hpt production using a murine tumor transplantation model. Methods: The relationship between Fuc-Hpt levels and clinical parameters was investigated in 77 patients with CRC, all of whom underwent primary resection. Serum Fuc-Hpt levels were examined in athymic nude mice injected with colon cancer cell lines that lacked fucosylation. Results: Fuc-Hpt levels were significantly associated with overall and relapse-free survival, distant metastasis, clinical stage, and curability. Multivariate analysis revealed that distant metastasis was an independent factor for increased Fuc-Hpt levels. The combination of Fuc-Hpt and CEA might be a better serologic marker to predict prognosis. Fuc-Hpt levels were higher in mice with direct injection of tumor cells into the spleen than in those injected subcutaneously. Conclusions: Fuc-Hpt might be a useful marker for the prognosis of CRC. Fuc-Hpt could be produced by the tissue surrounding tumor cells, which might be the mechanism underlying Fuc-Hpt elevation associated with distant metastasis.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4531. doi:1538-7445.AM2012-4531
Abstract 4533: Characteristics of HS6ST2 expression in colorectal cancer
Authors: Kimura Hideharu , Hatabe Shigeru , Arao Tokuzo , Hayashi Hidetoshi , Nagai Tomoyuki , Matsumoto Kazuko , Fujita Yoshihiko , Fukushima Masao , Ito Akihiko , Okuno Kiyotaka , Nishio Kazuto 
Published: August 2012

Abstract
Background. We have found that the gene expression of heparin sulfate D-glucosaminyl 6-O-sulfotransferase-2 (HS6ST2) is overexpressed in colorectal cancer in a previous study. Aims of this study are to evaluate the HS6ST2 expression in colorectal cancer tumor samples in relation to the clinicopathological features. Methods. The mRNA expression levels of HS6ST2 were analyzed in various cancer cell lines using real-time RT-PCR. HS6ST2 protein expression was evaluated using immunohistochemistry. Tumor specimens were obtained from 103 colorectal cancer patients operated in Kinki University Hospital. Results. High mRNA expression was observed in 2/15 (13%) of gastric cancer and 3/6 (50%) of colorectal cancer cell lines. In immunohistochemistry analysis, cytoplasm staining was found in cancer cells, not in normal colon cells, and positive staining of HS6ST2 expression was seen in 37 patients (36.3%). There were no relationships between clinicopathological features and HS6ST2 expression in cancer cells. Colon cancer patients with HS6ST2 expression tend to have worse overall survival (p = 0.097, Log-rank test).Conclusion. The cytoplasm expression of HS6ST2 is tumor-specific in colon tissues. HS6ST2 may contribute to be worse outcome.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4533. doi:1538-7445.AM2012-4533
Abstract 4568: Estrogen receptor and progesterone receptor immunocytochemistry staining in circulating tumor cells as compared to primary tumor or metastatic biopsy
Authors: Mayer Julie Ann , Pircher Tony J. , Pham Tam , Wong Karina , Villarin Eligie , Bischoff Farideh Z. 
Published: August 2012

Abstract
Introduction: Hormone receptor (estrogen receptor (ER) and progesterone receptor (PR)) status in all breast cancer patients is recommended by immunohistochemistry (IHC) and is considered standard practice for selection of treatment options. However, the analytical sensitivity of IHC in detecting low levels of ER/PR is often poor and likely due to methodological variation. Because biopsy is not often feasible in all patients presenting with recurrent and/or metastatic breast disease, circulating tumor cells (CTCs) offer an attractive alternative source of tumor tissue for determining ER/PR status and can be monitored more readily to enable a more effective course of treatment. Experimental Design: Twenty ml of peripheral blood was collected prospectively from 14 patients diagnosed with late stage metastatic/recurrent breast cancer. CTCs were isolated using the microfluidic OncoCEETM platform. A cocktail of antibodies was utilized for CTC capture and detection with an expanded anti-cytokeratin (CK) cocktail mixture and anti-CD45. ER/PR protein expression was assessed by immunocytochemistry (ICC) on the cells captured within the microchannels and compared to IHC performed on the primary tumor or metastatic biopsy. Results: CK+/CD45-/DAPI+ cells were located and assessed for ER/PR immunocytochemistry. Among the 14 cases a high concordance (12/14; 86%) in ER/PR status between primary tumor/metastatic biopsy and CTCs was observed. Two cases were found to be discordant where one was positive by IHC and negative on the CTCs and the other was negative on by IHC on the primary tumor/metastatic biopsy and positive on the CTCs. However, both cases that were discordant had low numbers of CTCs detected. Conclusions: There is significant heterogeneity between ER/PR protein expression in CTCs and primary tumor/metastatic biopsy and this status may change over time due to therapy. ER/PR ICC on CTCs from peripheral blood using the OncoCEETM platform is shown to be feasible with high concordance (86%) in ER/PR status between primary tumor/metastatic biopsy (by IHC) and CTCs (by ICC). The significance of heterogeneity at the ER/PR protein level in CTCs ascertaining to the prognosis and predictive response to anti-estrogen therapy needs further evaluation in larger prospective clinical trials.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4568. doi:1538-7445.AM2012-4568